Package Insert: Information for the User
Donepezilo SUN 5 mg Film-Coated Tablets EFG
Donepezil Hydrochloride
Read this entire package insert carefully before starting to take this medicine, as it contains important information for you
Contents of this package insert
Donepezilo belongs to a group of medicines called cholinesterase inhibitors. Donepezilo hydrochloride increases the levels in the brain of a substance related to memory (acetylcholine), by reducing the rate of breakdown of this substance.
It is used to relieve the symptoms of mild to moderately severe Alzheimer's disease.The symptoms include increased loss of memory, confusion, and changes in behavior.
Remember:Inform your doctor about your caregivers.
Do not take Donepezilo SUN:
Warnings and precautions:
Donepezil treatment should only be initiated and monitored by a doctor experienced in the diagnosis and treatment of Alzheimer's disease.
Do not take Donepezilo SUN with other acetylcholinesterase inhibitors and other cholinergic agonists or antagonists.
Children:
Donepezil is not recommended for use in children.
Other medications and Donepezilo SUN:
Inform your doctor or pharmacist if you are using, have used recently or may need to use any other medication, including those obtained without a prescription.
Especially, it is essential to inform your doctor if you are taking any of the following types of medications:1:
In the event of surgical intervention with general anesthesia, inform your doctor that you are taking Donepezilo SUN as this may affect the amount of anesthetic needed. Donepezilo SUN may be used in patients with mild to moderate kidney or liver disease. Inform your doctor if you have any kidney or liver disease. Patients with severe liver disease should not take Donepezilo SUN.
Donepezilo SUN with food, drinks and alcohol:
This medication should be taken with a little water.
Donepezilo SUN should not be taken with alcohol as alcohol may modify the effect of this medication.
Pregnancy, lactation and fertility:
If you are pregnant or breastfeeding, or think you may be pregnant or intend to become pregnant, consult your doctor or pharmacist before using this medication.
Do not take Donepezilo SUN if you are pregnant or think you may be pregnant.
Do not take Donepezilo SUN if you are breastfeeding your child.
Driving and operating machinery:
Alzheimer's disease may affect your ability to drive or operate machinery, and you should not engage in these activities unless your doctor indicates it is safe to do so. Donepezilo SUN may cause fatigue, dizziness, drowsiness and muscle cramps, mainly at the start of treatment or when increasing the dose. If you experience these effects, do not drive or operate machinery.
Donepezilo SUN contains lactose:
This medication contains lactose. If your doctor has indicated that you have a certain sugar intolerance, consult with them before taking this medication.
Donepezilo SUN contains sodium:
This medication contains less than 23 mg of sodium (1 mmol) per coated tablet; this is essentially "sodium-free".
Follow exactly the administration instructions for Donepezilo SUN as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
Donepezilo SUN is administered orally. The tablets should be swallowed with a little water.
The treatment with donepezilo starts with a 5 mg tablet, taken once a day, at night, immediately before going to bed. After a month of treatment, your doctor may recommend an increase in the dose to 10 mg, once a day and at night. The maximum recommended dose is 10 mg/day.
If you have abnormal dreams, nightmares, or difficulty sleeping (see section 4), your doctor may recommend that you take Donepezilo SUN in the morning.
If you have mild or moderate liver disease (a disease that affects the liver) or kidney disease (a disease that affects the kidney), you can take Donepezilo SUN. Inform your doctor before starting treatment if you have liver or kidney problems. Patients with severe liver disease should not take Donepezilo.
Use in children
Donepezilo SUN is not recommended for use in children.
If you take more Donepezilo SUN than you should
If you have taken more Donepezilo SUN than you should, consult your doctor, pharmacist, or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount used.
The symptoms of overdose may include nausea (feeling sick), vomiting (being sick), drooling, sweating, decreased heart rate, low blood pressure (dizziness or lightheadedness when standing up), breathing problems, loss of consciousness, and seizures
If you forgot to take Donepezilo SUN
Do not take a double dose to make up for the missed dose.
If you interrupt the treatment with Donepezilo SUN
Do not stop taking Donepezilo SUN unless your doctor tells you to. If you stop taking Donepezilo SUN, the benefits of treatment will gradually disappear.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, Donepezilo SUN may cause side effects, although not everyone will experience them.
The following side effects have been reported by people taking donepezilo.
Contact your doctor if you experience any of these side effects during treatment with Donepezilo SUN.
Severe side effects:
You should inform your doctor immediately if you notice any of the following severe side effects, as you may need urgent medical treatment.
- Liver damage, for example, hepatitis. The symptoms of hepatitis are nausea or vomiting (feeling or being sick), loss of appetite, general discomfort, fever, itching, yellowing of the skin and eyes, and dark-colored urine (affects between 1 and 10 out of 10,000).
- Ulcers in the stomach or duodenum. The symptoms of ulcers are stomach pain and discomfort (indigestion) between the navel and the breastbone (affects between 1 and 10 out of 1,000).
- Bleeding in the stomach or intestines. This can cause you to have black, tar-like stools or visible blood from the rectum (affects between 1 and 10 out of 1,000).
- Dizziness (attacks) or seizures (affects between 1 and 10 out of 1,000).
- Fever with muscle stiffness, sweating, decreased level of consciousness (may be symptoms of a condition called "Neuroleptic Malignant Syndrome") (affects fewer than 1 out of 10,000 patients).
- Weakness, sensitivity, or muscle pain, particularly if you also feel unwell, have a fever, or your urine is dark. This may be due to abnormal muscle destruction that can be fatal and cause kidney problems (a disease called rhabdomyolysis).
The estimated frequency of side effects is as follows:
Very common:may affect more than 1 in 10 patients
Common: may affect between 1 and 10 in 100 patients
Uncommon:may affect between 1 and 10 in 1,000 patients
Rare: may affect between 1 and 10 in 10,000 patients
Frequency unknown
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication
Keep this medication out of the sight and reach of children.
This medication does not require special storage conditions.
Do not use this medication after the expiration date that appears on the packaging. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Donepezilo SUN
Appearance of the product and content of the container
Donepezilo SUN tablets are circular, yellow in color, and marked with “RC25” on one side.
Donepezilo SUN is available in blisters. Each container contains 28 tablets.
Holder of the marketing authorization and Responsible for the manufacturing
Holder of the marketing authorization
Sun Pharmaceutical Industries Europe B.V.,
Polarisavenue 87,
2132JH Hoofddorp, Netherlands
Responsible for the manufacturing
Sun Pharmaceutical Industries Europe B.V.,
Polarisavenue 87,
2132JH Hoofddorp,
Netherlands
or
Terapia S.A.
Str. Fabricii nr. 124,
Cluj, Napoca,
Romania
You can request more information about this medication by contacting the local representative of the holder of the marketing authorization:
Sun Pharma Laboratorios, S.L.
Rambla de Catalunya 53-55
08007 Barcelona. Spain
Tel.: +34 93 342 78 90
Last review date of this leaflet:September 2022
The detailed information of this medication is available on the website of the Spanish Agency of Medicaments and Health Products (AEMPS) http://www.aemps.gob.es
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.